Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

Pharvaris N.V. discussed topline results from its Chapter-3 Phase III study of deucrictibant as a prophylactic treatment for hereditary angioedema. The provided article text does not disclose efficacy, safety, statistical outcomes, or regulatory implications, limiting assessment of the trial's financial impact.